XImmune develops pharmaceuticals to treat microbe-induced inflammatory conditions

XImmune is developing new effective treatments based on unique properties of new classes of endogenous host defense peptides discovered to display potent immune-modulating and anti-inflammatory properties. Sepsis is a major disease area for which efficient treatments are needed, and for which hospital-associated society economic burden is large and growing.

Product: Peptide-based anti-inflammatory treatment for sepsis.

Concept: Utilization of the body´s own endogenous peptides for anti-inflammatory purposes.

Stage: pre-CD

LU Bio position: 51,8%

Partners: LU Bio, Dermagen, Sparbankstiftelsen Skånes Riskkapitalstiftelse and inventors